ArticleBMC cancer2018
The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 5 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- The prognostic values of FOXP3Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Pooled it
- Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials.Frontiers in oncology · 2022Pooled it
- Elevated peripheral absolute monocyte count related to clinicopathological features and poor prognosis in solid tumors: Systematic review, meta-analysis, and meta-regression.Cancer medicine · 2021Pooled it
- Pooled it
- Folate intake and the risk of breast cancer: an up-to-date meta-analysis of prospective studies.European journal of clinical nutrition · 2019Pooled it
- Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.Frontiers in immunology · 2022Trial
- Article
- The Evaluation of Diagnostic, Prognostic, and Predictive Role of Hematologic Inflammatory Indices NLR, PLR, and LMR in Common Solid Tumors.Cancer reports (Hoboken, N.J.) · 2025Review
- Prognostic Value of Neutrophil-Lymphocyte Ratio Change After Short-Term Chemotherapy inJournal of breast cancer · 2025Article
- Serum Hepcidin Levels in Breast Cancer Patients: Investigating the Correlation to Tumor Stage-A Cross-Sectional Study.Health science reports · 2025Article
- Single-Cell Sequencing and Transcriptome Analysis Explored Changes in Midnolin-Related Immune Microenvironment and Constructed Combined Prognostic Model for Pancreatic Cancer.Journal of inflammation research · 2025Article
- Prognostic Role of Absolute Monocyte Count, CD163⁺ Macrophages, and CD8⁺ Lymphocytes in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.F1000Research · 2025Article
- Article
- Article
- Low Absolute Lymphocyte Count Correlates with Lymph Node Metastases and Worse Survival of Patients with Gastric Cancer.Annals of surgical oncology · 2024Article
- The Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors-Impact on Clinical Practice.Biomedicines · 2024Review
- Anti-Tumor Immunity to Patient-Derived Breast Cancer Cells by Vaccination with Interferon-Alpha-Conditioned Dendritic Cells (IFN-DC).Vaccines · 2024Article
- Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer.BMC cancer · 2024Article
- Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer.Scientific reports · 2024Article
- Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine.Pharmaceuticals (Basel, Switzerland) · 2024Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarcinogenesis and tumor growth are associated with chronic inflammation and the host immune system. Here, we investigated the clinical significance and relationship between tumor-infiltrating lymphocytes (TILs) and hematologic parameters in patients with breast cancer.
methodsInvasive ductal breast cancer patients (N = 145) who underwent surgery were retrospectively evaluated. Samples were obtained using a core needle biopsy for CD8+, FOXP3+ TIL assessment. Blood lymphocytes, neutrophils, monocytes, and platelets were obtained by peripheral venous punctures.
resultsCD8 + TILs were significantly associated with absolute lymphocyte count (ALC) and the absolute monocyte count (AMC). Low LMR (ALC/AMC) (cut-off - 5.3, range = 0.73-12.31) was associated with poor overall survival (OS) (p = 0.010), disease-free survival (DFS) (p = 0.005). However, in subgroup analysis, LMR did not have any value as a prognostic factor in HER2-positive breast cancers. TILs had different prognostic impacts across breast cancer subtypes, although they were not statistically significant. The treatment response after NAC tended to improve in breast cancer patients with high FOXP3+ TILs, low NLR (neutrophil count/ALC) (FOXP3 p for trend = 0.006, NLR p for trend = 0.063).
conclusionsA relevance between TILs and hematologic parameters in breast cancer was demonstrated. The influence of the immune system on breast cancer progression may differ by subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.